Daa Retreatment Vosevi denied due to quantity / dose limits by Cigna?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for daa retreatment vosevi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Daa Retreatment Vosevi
## Why Cigna Issues Quantity-Limit Denials for Vosevi (DAA Retreatment)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a direct-acting antiviral (DAA) regimen used for retreatment of chronic hepatitis C in patients who have failed a prior DAA-based therapy. Cigna applies quantity-limit criteria to this drug in part because retreatment regimens carry significant cost and because the clinical indication is tightly bounded — retreatment is appropriate only after confirmed prior DAA failure, not for initial therapy. When the plan's system does not clearly register the retreatment context, an automated quantity-limit denial is commonly generated.
## Why This Denial Is Appealable
Quantity-limit denials are presumptive — they are triggered by utilization-management rules before a clinical reviewer examines your specific case. If your prescriber documents that the requested course reflects the FDA-approved retreatment regimen exactly as written in the prescribing label, and that your prior DAA treatment history supports the indication, the quantity-limit rationale typically falls away on clinical review. Cigna is required under its own coverage policy and applicable state mandates to evaluate whether the requested quantity is medically necessary for the approved indication.
## Federal Appeal Framework
- Internal appeal (Level 1): Submit within the timeframe printed on your denial letter (commonly 180 days). Cigna must decide within 30 days for pre-service or 60 days for post-service claims.
- Expedited internal appeal: Available if your condition is urgent. Decision required within 72 hours.
- External review (ACA §2719 / ERISA §503): After exhausting internal appeals, you may request independent external review. The reviewer is not employed by Cigna. For non-urgent cases the window is approximately four months from the final internal denial; expedited external review is available for urgent situations.
## Documentation to Gather
1. Diagnosis confirmation — liver biopsy, FibroScan, or equivalent staging record; current genotype/subtype report; viral load labs. 2. Prior DAA treatment history — names of all prior regimens, start and stop dates, adherence documentation, and end-of-treatment/sustained virologic response labs confirming treatment failure or relapse. 3. Clinical severity — current hepatic function labs, fibrosis stage, any complications documented in the chart. 4. Prescriber medical-necessity letter — your hepatologist or gastroenterologist should state why Vosevi is the appropriate retreatment option per the FDA label and relevant specialty society guidelines (e.g., AASLD/IDSA HCV guidance), and why no alternative regimen is appropriate for your genotype/prior-treatment profile.
## Criteria-Mapping Structure
Print Cigna's published medical/coverage policy for Vosevi alongside the FDA-approved prescribing label. For each criterion listed, pull the exact matching fact from your medical record:
| Policy/Label Requirement | Chart Evidence | |---|---| | Confirmed chronic HCV diagnosis | [genotype report date + result] | | Prior DAA regimen and failure type | [prior drug, dates, SVR result] | | Retreatment indication per label | [prescriber attestation] | | Requested quantity matches label course | [days supply per prescribing label] |
A complete criteria-mapping letter, signed by your prescriber, is the single most effective document in a quantity-limit appeal.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →